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Summary
N-Myc oncogene amplification is a frequent event in neuroblastoma and is strongly correlated with advanced disease
stage and treatment failure. Similarly to c-Myc oncogenic activation, N-Myc deregulation promotes both cell proliferation
and p53-dependent apoptosis by sensitizing cells to a variety of insults. Intriguingly, p53 mutations are uncommon in
neuroblastomas, strongly suggesting that an alternative cooperating event circumvents this safeguard against oncogene-
driven neoplasia. By performing a pangenomic cDNA microarray analysis, we demonstrate that human Twist is constantly
overexpressed in N-Myc-amplified neuroblastomas. H-Twist overexpression is responsible for the inhibition of the ARF/
p53 pathway involved in the Myc-dependent apoptotic response. This oncogenic cooperation of two key regulators of
embryogenesis causes cell transformation and malignant outgrowth.
Introduction overexpression should sensitize cells to apoptosis, patients with
N-Myc-amplified neuroblastoma generally have very poor prog-
nosis, in spite of intensive chemotherapy (Brodeur, 2003). ToIt is now widely acknowledged that normal cells respond to
inappropriate growth signals, such as oncogenic activation, by date, studies have failed to identify oncogenes cooperating with
N-Myc in neuroblastoma development or to demonstrate theinducing genetically encoded programs that eliminate inappro-
priately proliferating cells from the cell cycle, thus protecting inactivation of any known tumor suppressor gene. In particular,
it was observed that, although the ARF-p53 pathway is themulticellular organisms from cancer progression. Amajor obsta-
cle to the expansion of cells with significant proliferative poten- primary failsafe cascade engaged by myc oncoproteins (Zindy
et al., 1998), p53 mutation is a rare event in N-Myc-amplifiedtial is the induction of programmed cell death that is normally
triggered in the presence of DNA damage or in conditions of neuroblastomas (Vogan et al., 1993). By using a pangenomic
cDNAmicroarray analysis, we detectedH-Twist overexpressionlimited supply of trophic factors. Consequently, oncogene-
driven proliferationmust be associatedwith inhibition of apopto- in N-Myc-amplified neuroblastomas. H-Twist protein is a tran-
scription factor of the basic-helix-loop-helix (bHLH) family,sis to allowmalignant outgrowth. This phenomenon is illustrated
which has been shown to play a crucial role during embryogene-by the acceleration of myc transgene-induced tumorigenesis in
sis. We demonstrate here that H-Twist acts as an oncogene inthe context of bcl-2 overexpression (Strasser et al., 1990) or
neuroblastoma by protecting cells from the proapoptotic effectp53 deletion (Elson et al., 1995).Myc oncoproteins are examples
of N-Myc through the inhibition of the ARF/p53 pathway.of factors promoting both growth and apoptosis (Evan et al.,
1992; Fulda et al., 1999). Despite this apparent dual activity,
Results and discussionthe activation of myc oncoproteins is a frequent event in human
cancers. Whereas the activation of c-Myc is detected in a wide
range of tumors, N-Myc amplification is observed in advanced With the aim to identify inhibitors of apoptotic pathways that
might be deregulated in synergy with N-Myc, we performed astages of neuroblastoma, a pediatric tumor that derives from
primitive sympathetic neural precursors (Brodeur et al., 1984). microarray analysis using U95Av2 gene chips (Affymetrix) in
neuroblastoma tumor specimens stratified for N-Myc amplifica-N-Myc amplification is generally associated with a very high
expression of the oncoprotein in cancer cells. Whereas N-Myc tion (see Supplemental Experimental Procedures at http://
S I G N I F I C A N C E
Resistance to programmed cell death and loss of p53 activity are common characteristics of human tumor cells. Our study demon-
strates the oncogenic cooperation of two major regulators of embryogenesis, N-Myc and H-Twist, in the development of neuro-
blastoma, the most common and deadly solid tumor of childhood. N-Myc induces cell proliferation, whereas H-Twist inhibits the
apoptotic response that is normally triggered by Myc overexpression. This dramatic cooperation allows cells to override cellular
failsafe programs, thus permitting tumor progression. Our observation provides a mechanistic explanation for the rarity of p53
mutations in neuroblastomas. It also highlights the oncogenic cooperation of two crucial regulators of embryogenesis, strongly
supporting the hypothesis that neuroblastoma originates from a developmental defect.
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mal and cranial neural crest cells during embryogenesis in both
invertebrate and vertebrate development and regulates meso-
derm determination, myogenesis, and morphogenesis (Leptin
and Grunewald, 1990; Hebrok et al., 1994). In mice, Twist is
essential for progression andmaintenance of limb bud morpho-
genesis. It functions through epithelial-mesenchymal signaling
and cell survival control via the modulation of SHH and FGF
signal transduction (O’Rourke et al., 2002). In humans, germline
mutations in the coding region of the H-Twist gene have been
found to account for the Saethre-Chotzen syndrome (SCS), an
autosomal-dominant hereditary disorder characterized by limb
abnormalities, facial dysmorphisms, and premature fusion of
cranial sutures (Howard et al., 1997; el Ghouzzi et al., 1997).
Numerous lines of evidences suggest that part of Twist’s func-
tion involves regulation of programmed cell death. It was re-
cently shown that, in SCS, H-Twist haploinsufficiency induces
calvarial osteoblast apoptosis (Yousfi et al., 2002). In animal
models, the homozygous inactivation of Twist provokes a mas-
sive wave of apoptosis during development (Chen and Beh-
ringer, 1995). Finally, in vitro, Twist has been shown to be able
to interferewith theARF-p53 pathway to prevent c-myc-induced
apoptosis in mouse embryonal fibroblasts (Maestro et al., 1999).
On the basis of these observations, we hypothesized that
H-Twist could disrupt the cellular failsafe reaction in neuro-
blastoma cells overexpressing N-Myc. In a first approach, we
sought to inhibit H-Twist expression by RNA interference in
human neuroblastoma cells, which endogenously overexpress
both N-Myc and H-Twist (WAC, CLB-Pe, IGRN91; see Figure
1B). As exemplified in Figure 2, a partial inactivation of H-Twist
Figure 1. H-Twist overexpression in N-Myc-amplified neuroblastoma tumors (Figures 2A and 2B) was sufficient to provoke massive apopto-
and cell lines sis, in all three cell lines, 48–72 hr after transfection. (Figures
A: H-Twist (gray bars) andN-Myc (black bars) mRNA expression in 18 N-Myc- 2C and 2D). This demonstrates that apoptotic pathways are
nonamplified (single copy [SC], 1–18) and in seven N-Myc-amplified (NMA,
functional in neuroblastoma cells overexpressingN-Myc but are1–7) neuroblastomas, as assessed by using U95Av2 Affymetrix microarrays.
inhibited by H-Twist. The apoptotic response was associatedData are reported as relative intensity signal after background correction
and normalization with MASS5.0 software (Affymetrix). with a significant increase of the caspase 3 activity, whereas
B: H-Twist mRNA levels were determined by quantitative real-time RT-PCR the activity of the caspase 8 was unchanged (Figure 2E).
in N-Myc-nonamplified (SC) and in N-Myc-amplified (NMA) human neuro- We then examined the possibility that N-Myc and H-Twistblastoma cell lines. Data were normalized by measuring the levels of RNaseP
might cooperate to promote malignant transformation. Loss ofmRNA. Means and standard errors are shown. H-Twist expression was corre-
anchorage dependence is a hallmark of tumor cells, and thelated to N-Myc and H-Twist protein levels, as assessed by Western blot
analysis. ability to promote anchorage-independent growth is a common
property of oncogenes. Therefore, we tested whether N-Myc
and H-Twist coexpression could promote the growth of early-
passage mouse embryo fibroblasts (MEFs) in semisolid media
www.cancercell.org/cgi/content/full/6/6/625/DC1/). As (Figure 3A). Whereas the expression of either H-Twist or N-Myc
shown in Figure 1A, H-Twist expression was observed in all was insufficient to obtain colonies in soft agar, their coexpres-
N-Myc-amplified tumors (seven of seven), whereas only 2 of 18 sion stimulated the formation of large colonies (1290  70 foci
nonamplified neuroblastomas showed detectable H-Twist gene for 5.104 primary MEF cells plated), demonstrating a strong
expression (Yates’ correction, 13.6; p 0.001). The association synergistic effect of the two genes.
of N-Myc upregulation and H-Twist expression in neuro- Previous observations suggested that the antiapoptotic
blastoma sampleswas confirmed by real-time polymerase chain properties of H-Twist might involve several mechanisms, includ-
reaction with reverse transcription (real-time RT-PCR) (data not ing modulation of TNF expression (Yousfi et al., 2002), regula-
shown). We then evaluatedH-Twist expression by real-time RT- tion of the NF-B signaling pathway (Sosic et al., 2003), and
PCR and Western blot analysis in a variety of human neuro- inactivation of the p53 pathway by downregulation of its up-
blastoma cell lines. As shown in Figure 1B, H-Twist expression stream regulator, ARF (Maestro et al., 1999). Since c-Myc-
was highly correlated to levels of N-Myc protein. Neuroblastoma induced cell death has been clearly demonstrated to be depen-
cell lines with N-Myc amplification exhibited a 16- to 164-fold dent on p53 in a number of experimental systems (Hermeking
higher level of H-TwistmRNA expression than nonamplified cell and Eick, 1994), we examined the possibility that H-Twist might
lines. protect N-Myc-amplified neuroblastoma cells by damping p53
H-Twist protein is an evolutionarily highly conserved tran- response. Like most neuroblastoma cells, human SHEP cells
scription factor that belongs to the family of bHLH proteins contain a wild-type p53 gene. These cells do not possessN-Myc
amplification, and endogenous H-Twist is undetectable, as(Olson and Klein, 1994). It is expressed specifically in mesoder-
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Figure 2. H-Twist inactivation by RNA interfer-
ence in human neuroblastoma cells (WAC, CLB-
Pe, and IgRN-91) restores apoptosis properties
and caspase 3 activities
A and B: H-Twist silencing efficiency was evalu-
ated at mRNA level by Northern analysis (A), and
protein level was evaluated by Western blotting
(B) on cell extracts corresponding to mock-trans-
fected cells (lane 1) or cells transfected with
scramble siRNA (lane 2), Twist3 siRNA (lane 3), or
Twist5 siRNA (lane 4). Example is given for WAC
cells.
C: H-Twist inactivation (Twist3 siRNA and Twist5
siRNA) causes neuroblastoma cell death as as-
sessed by measurement of subdiploid DNA con-
tent after staining with propidium iodide (PI) and
analysis by flow cytometry. Percentages of cells
in sub-G1 are indicated. Example is given for
WAC cells. Maximal gene silencing was ob-
tained for CLB-Pe (43%) with Twist3 siRNA com-
pared to the scramble control (13.5%). Northern
analysis (A),Western blotting (B), and flow cytom-
etry (C) were performed 72 hr after transfection.
D: Terminal transferase TUNEL staining of WAC
cells performed 72 hr posttransfection with
scramble siRNA (Db), Twist3 siRNA (Dd), or Twist5
siRNA (Df). Phase contrast images of correspond-
ing cells are presented in left raw (Da, Dc, and
De).
E: Caspase activity index of caspase 8 (upper
panel) and caspase 3 (lower panel) evaluated
on mock-transfected cells (pink bars) or cells
transfected with scramble siRNA (yellow bars),
Twist3 siRNA (blue bars), or Twist5 siRNA (dark
bars). Data are shown for WAC cells 24, 48, and
72 hr after transfection.
shown in Figure 1B. H-Twist-expressing SHEP cells (SHEP/ was able to transform Ink4a-ARF/ MEFs (152  40 foci for
5.104 primary MEF cells plated), confirming that H-Twist onco-Twist) and control cells (SHEP/PCI) were generated using plas-
mid expression vectors (Figures 4A and 4B). Control cells (pa- genic activity is partly due to the disruption of the ARF/p53
pathway. However, simultaneous overexpression of N-Myc andrental SHEP cells and SHEP/PCI cells) and four different stable
SHEP/Twist clones were then submitted to  irradiation to acti- H-Twist in Ink4a-ARF/ MEFs yielded higher number of colo-
nies (614  50 foci), strongly suggesting that H-Twist mightvate the p53 pathway. Levels of p53 protein and of its transcrip-
tional target, p21Waf1, were evaluated by Western blot analysis also interfere with ARF-independent pathways.
The striking association observed between N-Myc amplifi-3, 6, 9, and 24 hr postirradiation. As shown in Figure 4C, a
strong p53 inductionwas observed 3 hr postirradiation in control cation and H-Twist expression suggests that H-Twist might be
a transcriptional target of N-Myc in neuroblastoma cells. As aSHEP cells, leading to an increase of p21Waf1 expression. In
contrast, H-Twist-overexpressing cells were resistant to p53 preliminary experiment, we evaluated H-Twist expression in a
neuroblastoma cell line harboring an inducible expression ofresponse. Indeed, radiation exposure triggered only a weak
expression of p21Waf1 in all four tested clones (Figure 4C). No N-Myc (Lutz et al., 1996). In this system, N-Myc activation is
followed by a subsequent induction ofH-Twist expression (Sup-significant increase of p21Waf1 expression was observed in latter
time points (data not shown). The lack of p53 and p21Waf1 re- plemental Figure S1 at http://www.cancercell.org/cgi/content/
full/6/6/625/DC1/). However, in comparison to known directsponsewas associatedwith 3- to 4-fold increases of cell survival
as evaluated by TUNEL assay (data not shown). Our observation transcriptional targets of N-Myc (such as ornithine decarboxyl-
ase),H-Twist induction is significantly delayed, suggesting that itis consistent with the previous finding that, in rodent cells, Twist
inhibits the p53 pathway by downregulating ARF expression may be a secondary event. Additional experiments are currently
performed to confirm this hypothesis.(Maestro et al., 1999). On this basis, we speculated that experi-
mental ARF inactivation might replace H-Twist overexpression In neuroblastomas, N-Myc amplification is predominantly
associated with rapid neoplastic progression and a poor out-to promote cell transformation in the presence of N-Myc. To
test this hypothesis, growth of Ink4a-ARF/ MEFs transfected come. Numerous data demonstrate that N-Myc overexpression
sensitizes cells to cell death, strongly suggesting that inhibitionwith N-Myc or H-Twist, used either alone or together, was stud-
ied in soft agar assays (Figure 3B). In contrast toH-Twist,N-Myc of this apoptotic response is a crucial process for tumor progres-
CANCER CELL : DECEMBER 2004 627
R E P O R T
Figure 3. Oncogenic cooperation between H-Twist and N-Myc
A: Passage 4 primary MEF cells were transfected with empty plasmid (control), N-Myc, and/or H-Twist expression plasmids as indicated. Cells were then
analyzed for growth in soft agar. Photographs were taken 21 and 50 days after plating in soft agar, as indicated.
B: Ink4a-ARF/ MEFs cells were transfected with control, N-Myc, and/or H-Twist expression plasmids as indicated. Cells were then analyzed for growth in
soft agar. Photographs were taken 21 days after plating in soft agar, as indicated.
C: Nude athymic mice received a single subcutaneous injection with 106 SHEP neuroblastoma cells expressing the following: control empty vector (SHEP/
PCI) (open squares); H-Twist vector (SHEP/Twist) (filled triangle); H-Twist N-Myc (SHEP/H-Twist N-Myc) (filled squares). Tumor growth was monitored every
3–4 days after injection. Tumor volume was evaluated as V  Lxl2 	 0.52 (L corresponds to width and l to length of tumor).
Figure 4. Modulation of p53 response to geno-
toxic stress by H-Twist in neuroblastoma SHEP cells
A: Control (parental SHEP and SHEP/PCI) and
H-Twist-overexpressing (SHEP/Twist) cells were
analyzed for H-Twist mRNA expression, as as-
sessed by Northern blot analysis. GAPDH mRNA
levels are shown as loading control.
B: H-Twist protein levels in transfected cells as
evaluated by Western blot analysis. 
-actin was
used as a loading control.
C: Parental SHEP, SHEP/PCI, and SHEP/Twist cells
were submitted to 10 Gy  irradiation (IR). p53
and p21waf1 protein levels were determined 3, 6,
and 9 hr (t3, t6, t9) after IR by performing Western
blot analysis. A representative clone of SHEP/
Twist cells is shown.
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Plasmids and constructssion. Understanding this process has both cognitive and clinical
Cosmid pMp34.1-containing N-Myc sequences were previously describedimplications, since conventional cytotoxic chemotherapy exerts
(Schwab et al., 1985). H-Twist cDNA (provided by Dr. Fabienne Perrin-
its effects by triggering apoptosis. Several mechanisms, such Schmidt) was placed under the control of CMV promoter by cloning into
as hypermethylation of regulatory sequences of caspase 8 gene, pCI-NeoVector (Promega) after EcoRI restriction enzyme digestion (pCI-
cytoplasmic sequestration of the p53 protein, or Bcl2 overex- Twist vector).
pression, have previously been reported (Hogarty, 2003). How-
Tumorigenicity assaysever, none of these has been clearly shown to cooperate with
Nude athymic mice were kept in a sterile atmosphere at the Centre Le´onN-Myc activation. Our findings describe a novel mechanism
Be´rard animal facilities. Mice received a single subcutaneous injection with
by establishing H-Twist as a crucial inhibitor of N-Myc-primed neuroblastoma cells (106), and tumor growth was monitored every 3 days.
apoptosis. Since p53 response to deregulated Myc (c-Myc or
Protein lysate preparation and immunoblottingN-Myc) is known to be a crucial event toward apoptosis, the
Cell pellets were lysed 30 min on ice in cold lysis buffer (20 mM Tris-HClobservation that H-Twist oncogenic activity occurs, at least
[pH 7.6], Triton X-100, 0.05% SDS, 0.5% Na deoxycholate, 150 mM NaCl)partly, through the inhibition of the ARF/p53 pathway is particu-
containing 0.5mMPMSFand protein inhibitor cocktails (Sigma). Total protein
larly relevant. It also gives a mechanistic explanation for the (50–100 g) was separated on an SDS-PAGE. Western blot analysis was
rarity of p53 mutations in primary neuroblastomas. performed using mouse monoclonal N-MYC antibody (#556438; BD-Phar-
mingen), rabbit polyclonal H-Twist antibody (Agro-Bio France), mousemono-The hypothesis of an oncogenic cooperation between
clonal p53 antibody (#M7001, Dako), and p21waf1 antibody (#M7202; Dako).H-Twist and N-Myc in neuroblastoma is further supported by
preliminary data showing that H-Twist-expressing SHEP cells
RNA preparation and Northern blotting
(SHEP/Twist) or control SHEP cells (SHEP/PCI) are nontumori- RNA was extracted using the TriReagent solution (Sigma) on Phase Lock Gel
genic, whereas nude mice injected with SHEP cells overex- Heavy tubes (Eppendorf). Total RNA (10g)was separated on formaldehyde-
MOPS-gel, blotted to Hybond N membranes (Amersham), and hybridizedpressing both H-Twist and N-Myc develop tumors (five of five
with randomly dCT32P-primed H-Twist cDNA probes with Rediprime IImice) with a short latency period (Figure 3C). It is particularly
(Amersham) into CHURCH buffer (1 M Na2HPO4, 1 M NaH2PO4, 7% SDS,striking to observe the oncogenic cooperation of two key regula- 1% BSA), according to the manufacturer’s protocol.
tors of embryogenesis in neuroblastomas, strongly supporting
the current hypothesis that neuroblastoma originates from a Real-time RT-PCR
Total RNA was extracted, treated with DNase I, and reverse transcribed todevelopmental defect and is therefore an embryonal tumor.
synthesize complementary DNA using the First Strand cDNA Synthesis KitDuring the processing of this manuscript, Yang and collabo-
(Amersham). Quantitative real-time PCR was carried out with the Taq-man
rators (Yang et al., 2004), in an experimental animal model, Master Mix (Applied Biosystems) and analyzed using the ABI-PRISM 7000
reported the identification of H-Twist as a key factor of the Sequence Detection System. Specific primers and probes were as follows.
metastatic process of malignant mammary epithelial cells. They For N-Myc, 5-TGATGAAGAGGAAGATGAACAGG-3 (sense); 5-TCTTGG
GACGCACAGTGATG-3 (antisense); probe Fam-ACTGTGGAGAAGCGGfurther demonstrate that H-Twist expression results in loss of
CGTTCCTCCT-Tamra. For H-Twist, 5-GGACAAGCTGAGCAAGATTCAGA-E-cadherin-mediated cell-cell adhesion and induction of cell
3 (sense); 5-TCTGGAGGACCTGGTAGAGGAA-3 (antisense); probe Fam-motility, suggesting that it may play a role in the epithelial-
AGCTGGCGGCCAGGTACATCGA-Tamra. The expression of each genewas
mesenchymal transition. Furthermore, they report the overex- normalized using RNaseP as a reference (Applied Biosystems), and relative
pression of H-Twist in a significant fraction of invasive lobular levels were quantified by calculating 2Ct, where Ct is the difference in
Ct between target and reference, relative to SHEP cells.carcinoma. Previously, H-Twist was found to be upregulated in
gastric cancers (Rosivatz et al., 2002) and in rhabdomyosarco-
RNA interferencemas (Maestro et al., 1999). Together with our observations in
Short interfering RNA (siRNA) sequences targeting H-Twist corresponded
high-grade neuroblastomas, and the functional link between to the coding regions 55–75 (Twist5 siRNA) and 507–527 (Twist3 siRNA)
H-Twist, Myc oncoproteins, and p53, these studies suggest that relative to the first nucleotide of the start codon. A scramble siRNA (AGCGC
GCTTTGTAGGATTCG) was designed and used as control. Selected siRNAH-Twist may play an oncogenic role in a wide variety of human
sequences were submitted to a BLAST search against the human genomecancers.
sequence to ensure specificity. siRNAwere transfected as duplexes by using
Exgen 500 (MIB Fermentas) according to the manufacturer’s protocol.Experimental procedures
Apoptosis analysisCell culture, transfections, and selection procedure
Cell death analysis was assessed by trypan blue exclusion, TUNEL assayNeuroblastoma cell lines were previously described (Thiele, 1999; Lutz et
(Boehringer Mannheim), and measurement of subdiploid DNA content after
al., 1996) and cultured at 37C, under 5% CO2, using RPMI 1640 medium staining with propidium iodide (PI) and analysis by flow cytometry as de-
supplemented with 10% calf serum, 2% L-glutamine, and penicillin/strepto-
scribed (Arango et al., 2001).
mycin solution (10,000 U/ml; 10,000 g/ml) (GIBCO Invitrogen Corporation).
Cell lines were transfected using Exgen 500 (MIB Fermentas) according to Caspase activities
the manufacturer’s recommendations. Wild-type and Ink4a-Arf/ MEF cells Cell pellets were homogenized in lysis buffer according to themanufacturer’s
were provided by Dr. Van Lohuizen and cultured in DMEM medium under protocol (ApoAlert, Clontech). Fluorogenic substrates for caspase 3 (Ac-
same conditions (GIBCO). DEVD-AFC) and caspase 8 (Ac-IETD-AFC) were used, and caspase activities
were measured using a spectrofluorometer (Victor, Wallac).
Soft agar transformation assay
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